IBT
NVAX icon

International Biotechnology Trust’s Novavax NVAX Stock Holding History

International Biotechnology Trust’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-132,500
Closed -$925K – 73
2023
Q1 		$925K Hold
132,500
– – 0.26% 50
2022
Q4 		$1.36M Hold
132,500
– – 0.42% 44
2022
Q3 		$2.41M Buy
132,500
+125,686
+1,845% +$5.45M 0.77% 38
2022
Q2 		$133K Sell
6,814
-125,686
-95% -$6.51M 1.38% 23
2022
Q1 		$18.5M Buy
+132,500
New +$11.8M 4.18% 7

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

International Biotechnology Trust's NVAX Position: Q2 2023 in Review

International Biotechnology Trust sold out of Novavax (NVAX) in Q2 2023, closing a stake of 132,500 shares — an estimated $925K sold.

International Biotechnology Trust first reported a position in NVAX in Q1 2022 and held it in 5 quarters. The position peaked at $18.5M in Q1 2022. 215 funds tracked by Wall St. Rank hold NVAX as of Q2 2023.

  • International Biotechnology Trust reported no remaining Novavax position as of Q2 2023 after selling out during the quarter.
  • International Biotechnology Trust sold 132,500 Novavax shares in Q2 2023, an estimated $925K.
  • International Biotechnology Trust first reported a position in Novavax in Q1 2022 and held it in 5 quarters.
  • International Biotechnology Trust's Novavax position peaked at $18.5M in Q1 2022.
  • 215 funds tracked by Wall St. Rank held Novavax as of Q2 2023.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.